MELACAN™

Targets 46 key genes in melanoma

Melanoma is the most serious type of skin cancer. Treatment for melanoma depends on the size and stage of cancer. While surgical removal may be adequate for early-stage small melanomas, when it spread beyond the skin, chemotherapy, radiation therapy, targeted therapy or immunotherapy may be needed. To date, multiple targeted therapies (e.g. BRAF and MEK inhibitors) and immunotherapies (e.g. PD-1 and CTLA-4 inhibitors) have been approved by FDA to treat advanced melanoma.

  • Detects driver mutations in melanoma such as BRAF, MEK, c-KIT and NRAS to inform targeted therapy options 
  • Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers 
  • Assesses genetic predisposition for melanoma 
WHO IS IT FOR
  • Melanoma patients seeking precision medicine
  • Patients with unresectable or metastatic melanoma
  • Melanoma patients with recurrent disease 
SAMPLE TYPES
Icon Tumour Tissue

Tumor tissue (FFPE block/slides, or frozen tissue)

Icon Fine Needle Biopsy

Fine needle biopsy

Icon Liquid Biopsy

Liquid biopsy (plasma and others)

THYROCAN™

Targets 50 key genes in thyroid cancer 

Thyroid cancer develops from the thyroid gland. Although thyroid cancers are curable with treatments such as surgery, hormone therapy, radioactive iodine and the most common types of thyroid cancer, papillary and follicular subtypes by external radiation therapy. One-tenth of such patients will have recurrent disease.

However, medullary thyroid cancer has a worse prognosis and may also be genetically inherited. Anaplastic thyroid cancer is the most aggressive form of thyroid cancer. Several targeted therapies with kinase inhibitors have been approved to treat non-responsive radioactive iodine patients with differentiated papillary and follicular thyroid cancers as well as medullary and anaplastic thyroid cancer patients. 

  • Detects driver mutations in thyroid cancer such as BRAF, RET and RAS to inform targeted therapy options
  • Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers
  • Assesses genetic predisposition for thyroid cancer 
WHO IS IT FOR
  • Thyroid cancer patients seeking precision medicine 
  • Differentiated papillary and follicular thyroid cancer patients resistant to radioactive iodine therapy 
  • Medullary and anaplastic thyroid cancer patients 
SAMPLE TYPES
Icon Tumour Tissue

Tumor tissue (FFPE block/slides, or frozen tissue)

Icon Fine Needle Biopsy

Fine needle biopsy

Icon Liquid Biopsy

Liquid biopsy (plasma and others)

RETINOBLASTOMA GENETIC TESTING

Identify genetic predispositions fast

Retinoblastoma (RB) is a cancer that originates in the retina and affects young children in one (unilateral, ~60%) or both (bilateral, ~40%) eyes. It is mostly caused by RB1 gene mutations and the RB1 mutation can be inherited from one parent (~10%). Individuals that inherit RB1 mutation on one copy of the RB1 gene is predisposed to RB and other cancers later in the life when the second RB1 gene is also damaged in the tumor.

The majority of RB (~90%) develops spontaneously pre-conception or during early development of the fetus and is not heritable to future offspring. Therefore, RB1 genetic testing is critical for RB patients to assess the likelihood of developing additional tumors in the eye, to monitor the spread of cancer and improve surveillance and treatment of family members.  

  • Analyzes mutations in 27 exons, splicing sites flanking the exons and key promoter region of RB1 gene at germline, somatic and mosaic level 
  • Detects whole gene or exon-level copy number variation (CNV) of RB1 gene 
  • Optional validation test for family members of proband 
WHO IS IT FOR
  • Patients with unilateral or bilateral RB 
  • Parents of RB patients with confirmed RB1 mutation  
  • Individuals with one or more immediate family members with RB 
SAMPLE TYPES
Icon Tumour Tissue

Tumor tissue (FFPE block/slides, or frozen tissue)

Peripheral blood

SARCOPACT™

Targets 481 key genes in soft tissue and bone tumors

Sarcomas are designated as soft tissue or bone sarcomas, depending on where it originates in the body. Soft tissue sarcomas develop in fat, muscle, nerves, fibrous tissues, blood vessels or deep skin tissues while bone sarcomas arise in bone.

Treatment options vary depending on the size, location and type of tumor. Generally, surgery, radiation therapy, chemotherapy and targeted drug treatment are considered. Patients with localized sarcomas have a high probability of complete recovery with surgery. However, despite the effectiveness of traditional therapies, 50% patients develop metastasis and 10-20% experience recurrence. Currently, immunotherapy options rely on immuno-monitoring for prognosis and immuno-profiling subtypes. Immunotherapy harnesses the body’s natural ability to target disease, but enhancing them to specifically target cancer cells. There are numerous ongoing immunotherapy clinical trials investigating the role of checkpoint receptors such as PD-1/PD-L1 and CTLA-4 as predictive biomarkers in sarcoma. Adoptive cell therapy trials, whereby tumor infiltration lymphocytes (TILs) attack primary cancer cells are also underway for advanced sarcoma patients.

Current approved targeted therapies for sarcomas include cell cycle inhibitors (CDKIs) and tyrosine kinase inhibitors (TKIs). Molecular-targeted therapy have significantly improved prognosis for certain sarcomas (ie. GISTs), which are intrinsically resistant to chemotherapy and radiation.

  • Detection of single nucleotide variants (SNVs), small insertions and deletions (indels), gene fusions, copy number variations (CNVs), and gene translocations to characterize tumor subtypes
  • Coverage of prognosis-related genes to inform treatment decision making
  • Coverage of sarcoma-related, and clinically actionable gene alterations to guide targeted therapy
  • Assesses key biomarkers including tumor mutation burden (TMB), micro satellite instability (MSI), and DNA mismatch repair (MMR) genes to guide immunotherapy decisions
  • Timely assessment of drug resistance and associated mechanism(s) through liquid biopsy to direct treatment strategy
  • Hereditary cancer risk assessment for early intervention 
WHO IS IT FOR
  • Sarcoma patients seeking precision medicine
  • Patients with unresectable or metastatic sarcoma
  • Sarcoma patients with recurrent disease 
SAMPLE TYPES
Icon Tumour Tissue

Tumor tissue (FFPE block/slides, or frozen tissue)

Icon Fine Needle Biopsy

Fine needle biopsy

Icon Liquid Biopsy

Liquid biopsy (plasma and others)

LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.

Learn more about our products and services or contact us today to discuss how we can partner together.

Contact Us